Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut

Earnings

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty Images

Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn’t dim Eli Lilly’s bright multiyear outlook, rendering the dip in the stock as a chance to buy.

Articles You May Like

Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
The Quality Of Medicare Advantage Plans…Ain’t What It Used To Be.
United Airlines raises spending requirements to earn frequent flyer status
I just bought a Jeep for my teen driver. Here’s what I learned about the used car market
For investors, ‘there are a number of reasons to be bullish,’ JPMorgan strategist says

Leave a Reply

Your email address will not be published. Required fields are marked *